Clinical Trial

Disease: Relapsed or Refractory Multiple Myeloma, MM, (NCT05000450)

Disease info:

Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the centre of most bones. Multiple myeloma is characterised by abnormalities in plasma cells, a type of white blood cell. In myeloma, these abnormal cells multiply uncontrollably, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumours within the bone, causing bone pain and an increased risk of fractures.

Relapsed myeloma refers to when a patient had active treatment that their disease responded to, went off treatment and then the disease came back. 

Refractory myeloma is a disease that is progressing despite active treatment.

 

Frequency:
Multiple myeloma occurs in approximately 4 per 100,000 people per year; there are currently about 100,000 affected individuals in the United States.
Official title:
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Who:

Contact

Allogene Therapeutics

Phone: 415-650-0034

Email: clinicaltrials@allogene.com

Partners:
Locations:

United States, Colorado

Sarah Cannon/Colorado Blood Cancer Institute, Denver, Colorado, United States, 80218

 

United States, Texas

St. David's South Austin Medical Center, Austin, Texas, United States, 78704

MD Anderson Cancer Center, Houston, Texas, United States, 77030

Texas Transplant InstituteRecruitingSan Antonio, Texas, United States, 78229

Study start:
Jun. 6, 2021
Enrollment:
136
Gene editing method:
TALEN
Type of edit:
Gene knock-out, gene knock-in
Gene:
CD52 molecule, T-Cell Receptor Alpha Constant (TRAC), B-Cell Maturation Antigen (anti-BCMA CAR)
Delivery method:
Lentivirus (LV), electroporation - Ex-vivo
IndicatorIndicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

Allogene developed the TurboCAR technology to further enhance the potency of cell therapies. This technology allows ligand independent, cytokine signaling to be engineered selectively into CAR T cells. TurboCARs have the potential to enhance AlloCAR T cell proliferation and overcome T cell exhaustion

ALLO-605: B-Cell Maturation Antigen (BCMA) CAR T cells were generated from healthy donor T cells by lentiviral transduction with a CAR construct followed by genetic inactivation of the T-Cell Receptor Alpha Constant (TRAC) and CD52 loci using TALEN gene editing. Allogeneic BCMA TurboCAR T cells, engineered for stoichiometric expression of the CAR and a Constitutively Active Chimeric Cytokine Receptor (CACCR) via a self-cleaving peptide, were produced similarly.

Last updated: Dec. 28, 2023
close
Search CRISPR Medicine